In a new episode of the pharmaphorum podcast, web editor Nicole Raleigh welcomes Dr Carl Marci, chief psychiatrist and managing director of mental health and neuroscience at OM1 to discuss
A digital therapeutic (DTx) designed to help women cope with mood disturbances after giving birth has been shown to be effective in a randomised clinical trial, according
Sage Therapeutics has said it will cut its headcount by 40% in the wake of the narrower-than-hoped approval of its flagship antidepressant Zurzuvae by the FDA, with two of
Sage Therapeutics is facing the possibility of job losses and other cutbacks in the wake of the narrower-than-hoped approval of its flagship antidepressant Zurzuvae by the
Biogen and Sage Therapeutics' zuranolone has become the first oral drug to be approved by the FDA for post-partum depression (PPD), but the US regulator turned down a requ
Following DTx West 2023 in San Mateo, California, back in February, Woebot Health’s chief clinical officer Athena Robinson spoke with pharmaphorum about the conversations had at the event,
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.